Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.45
Bid: 3.40
Ask: 3.50
Change: 0.15 (4.55%)
Spread: 0.10 (2.941%)
Open: 3.40
High: 3.45
Low: 3.33
Prev. Close: 3.30
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Allergy Therapeutics Appoints Skyepharma's Wykeman As Finance Director

Fri, 10th Jun 2016 07:41

LONDON (Alliance News) - Allergy vaccination developer Allergy Therapeutics PLC on Friday said it has appointed former Skyepharma PLC Financial Controller Nick Wykeman as finance director with immediate effect.

Wykeman was financial controller at respiratory drug developer Skyepharma until August 2015. Skyepharma was bought by Vectura Group PLC in a deal which completed on Friday.

"We welcome Nick to his role as finance director and look forward to his contribution to the company as we continue to grow the business internationally on all fronts. His international experience in life sciences is well suited to the role and we're pleased to have attracted him to Allergy Therapeutics," Chairman Peter Jensen said in a statement.

Wykeman replaces Ian Postlethwaite who is moving to healthcare technology group NetScientific PLC to become its chief financial officer.

NetScientific confirmed Postlethwaite will join the company on Monday.

"We are pleased to welcome Ian as our new chief financial officer. This is an important period for NetScientific as we move forward with a renewed focus on digital health, diagnostics and therapeutics. Ian's extensive experience in the healthcare sector and the capital markets will prove invaluable as the company continues to progress," Chairman Richard Sykes said.

Shares in Allergy Therapeutics were untraded on Friday morning, last quoted at 24.90 pence, while shares in NetScientific were also untraded, last quoted at 79.80p.

By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
26 Oct 2020 14:17

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

Read more
26 Oct 2020 13:37

Allergy Therapeutics screens first patients in grass pollen study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.

Read more
23 Sep 2020 14:02

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

Read more
4 Sep 2020 19:39

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

Read more
3 Sep 2020 15:31

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax

(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
15 Jul 2020 09:03

Allergy Therapeutics revenues grow despite Covid-19 disruption

(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.

Read more
9 Jul 2020 21:19

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

Read more
9 Jul 2020 16:26

Allergy Therapeutics pleased with invalidation of B301 trial data

(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the primary endpoint data of the Birch MATA MPL pivotal phase 3 clinical trial, or 'B301', on Thursday.

Read more
24 Jun 2020 11:53

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Read more
24 Jun 2020 10:12

Allergy Therapeutics on track to 'significantly' exceed FY expectations

(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.

Read more
4 Mar 2020 10:46

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Read more
26 Feb 2020 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
16 Jan 2020 13:28

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Read more
26 Nov 2019 14:15

Allergy Therapeutics to take 'stepwise approach' to upcoming grass study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further investigation of the phase 3 birch MATA MPL study, the upcoming grass study would now take a 'stepwise approach'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.